Robocath
About the deal
ST. LOUIS and ROUEN, France, April 15, 2026 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has entered into a definitive agreement to acquire Robocath, a venture-backed innovator of robotic technologies for interventional cardiology and neurointerventions.
This acquisition significantly strengthens Stereotaxis’ position as a leading platform for the full spectrum of endovascular procedures, combining complementary technologies to deliver next-generation fully-integrated robotic solutions for electrophysiology, interventional cardiology and neurointerventions.
“It was a genuine pleasure working with the Agile team throughout this transaction. I would like to sincerely thank you for your unwavering professionalism, exceptional responsiveness, and highly valuable strategic guidance at every stage of the process. Your expertise and commitment were instrumental in navigating the complexity of this transformative deal and in ensuring its successful completion. It has been a true privilege collaborating with you, and I greatly appreciated the quality of our interactions and the trust built along the way.”
– Philippe Bencteux, CEO, Robocath